NATCO Pharma updates on acquisition of Adcock Ingram

iRegene Therapeutics secures series B+ financing

NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation

A.forall expands US generics portfolio

Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach

LGC opens CAD $100 million organic chemistry Center of Excellence in Canada

Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety

Lonza appoints Jason Berndt as Head of Group Operations

Maria Soler Nunez appointed as Chief Quality Officer

Briefs: Torrent Pharmaceuticals and Hemant Surgical Industries

Hemant Surgical Industries receives order

Dr. Reddy’s acquires J&J’s Stugeron portfolio to foray into anti-vertigo segment

The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions

Novo Nordisk to cut 9,000 jobs globally

Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients

Evonik and Ethris partner to expand offerings for nucleic acid delivery

Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support

Novartis to acquire Tourmaline Bio for $1.4 billion

Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease